Literature DB >> 30909811

Understanding the enzyme-ligand complex: insights from all-atom simulations of butyrylcholinesterase inhibition.

Walter Alvarado1, Parker Ladd Bremer2, Angela Choy3, Helen N Dinh2, Aingty Eung4, Jeannette Gonzalez5, Phillippe Ly2, Trina Tran2, Kensaku Nakayama2, Jason P Schwans2, Eric J Sorin2.   

Abstract

All-atom molecular dynamics simulations of butyrylcholinesterase (BChE) sans inhibitor and in complex with each of 15 dialkyl phenyl phosphate derivatives were conducted to characterize inhibitor binding modes and strengths. Each system was sampled on the 250 ns timescale in explicit ionic solvent, for a total of over 4 μs of simulation time. A K-means algorithm was used to cluster the resulting structures into distinct binding modes, which were further characterized based on atomic-level contacts between inhibitor chemical groups and active site residues. Comparison of experimentally observed inhibition constants (KI) with the resulting contact tables provides structural explanations for relative binding coefficients and highlights several notable interaction motifs. These include ubiquitous contact between glycines in the oxyanion hole and the inhibitor phosphate group; a sterically driven binding preference for positional isomers that extend aromaticity; a stereochemical binding preference for choline-containing inhibitors, which mimic natural BChE substrates; and the mechanically induced opening of the omega loop region to fully expose the active site gorge in the presence of choline-containing inhibitors. Taken together, these observations can greatly inform future design of BChE inhibitors, and the approach reported herein is generalizable to other enzyme-inhibitor systems and similar complexes that depend on non-covalent molecular recognition.Communicated by Ramaswamy H. Sarma.

Entities:  

Keywords:  Organophosphate; contact table; docking; omega loop; reversible inhibition

Mesh:

Substances:

Year:  2019        PMID: 30909811      PMCID: PMC6851450          DOI: 10.1080/07391102.2019.1596836

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  48 in total

Review 1.  Neurobiology of butyrylcholinesterase.

Authors:  Sultan Darvesh; David A Hopkins; Changiz Geula
Journal:  Nat Rev Neurosci       Date:  2003-02       Impact factor: 34.870

2.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

3.  Butyrylcholinesterase (BChE) activity is associated with the risk of preeclampsia: influence on lipid and lipoprotein metabolism and oxidative stress.

Authors:  Zohreh Rahimi; Reza Ahmadi; Asad Vaisi-Raygani; Ziba Rahimi; Fariborz Bahrehmand; Abbas Parsian
Journal:  J Matern Fetal Neonatal Med       Date:  2013-05-23

4.  Selective in vitro and in silico butyrylcholinesterase inhibitory activity of diterpenes and rosmarinic acid isolated from Perovskia atriplicifolia Benth. and Salvia glutinosa L.

Authors:  F Sezer Senol; Sylwester Ślusarczyk; Adam Matkowski; Alfonso Pérez-Garrido; Francisco Girón-Rodríguez; José P Cerón-Carrasco; Helena den-Haan; Jorge Peña-García; Horacio Pérez-Sánchez; Krzysztof Domaradzki; Ilkay Erdogan Orhan
Journal:  Phytochemistry       Date:  2016-11-03       Impact factor: 4.072

5.  Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.

Authors:  Satish N Dighe; Girdhar Singh Deora; Eugenio De la Mora; Florian Nachon; Stephen Chan; Marie-Odile Parat; Xavier Brazzolotto; Benjamin P Ross
Journal:  J Med Chem       Date:  2016-07-26       Impact factor: 7.446

6.  Alkynyl and β-ketophosphonates: Selective and potent butyrylcholinesterase inhibitors.

Authors:  Valeria Cavallaro; Yanina F Moglie; Ana P Murray; Gabriel E Radivoy
Journal:  Bioorg Chem       Date:  2018-02-20       Impact factor: 5.275

Review 7.  Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?

Authors:  E Giacobini
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

8.  Catalytic mechanism and energy barriers for butyrylcholinesterase-catalyzed hydrolysis of cocaine.

Authors:  Chang-Guo Zhan; Daquan Gao
Journal:  Biophys J       Date:  2005-12       Impact factor: 4.033

9.  Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.

Authors:  M R Farlow; P A Cyrus
Journal:  Dement Geriatr Cogn Disord       Date:  2000 Jul-Aug       Impact factor: 2.959

10.  Serum Butyrylcholinesterase Activity: A Biomarker for Parkinson's Disease and Related Dementia.

Authors:  Mei-Xue Dong; Xiao-Min Xu; Ling Hu; Yang Liu; Yuan-Jun Huang; You-Dong Wei
Journal:  Biomed Res Int       Date:  2017-08-03       Impact factor: 3.411

View more
  1 in total

Review 1.  A Comprehensive Review of Cholinesterase Modeling and Simulation.

Authors:  Danna De Boer; Nguyet Nguyen; Jia Mao; Jessica Moore; Eric J Sorin
Journal:  Biomolecules       Date:  2021-04-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.